Not Tagged
Not Tagged
[]
 that, i think, is the benefit of pros as a secondary endpoint &gt; coprimary. if you are studying an anti-inflammatory drug, control of inflammation should be the primary endpoint. secondary benefits (pros) should also be measured. using a coprimary does often push down pbo rates..
Physician-scientist studying inflammatory bowel disease, reproducible medical research. Chair-elect of CCF NSAC. #rstats #USMNT #Zwift